These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24548821)

  • 1. Clinical evidence of statin therapy in non-dyslipidemic disorders.
    Ferri N; Corsini A
    Pharmacol Res; 2014 Oct; 88():20-30. PubMed ID: 24548821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Roles of Statins in Gynecology and Obstetrics: The Current Evidence.
    Zeybek B; Costantine M; Kilic GS; Borahay MA
    Reprod Sci; 2018 Jun; 25(6):802-817. PubMed ID: 29320955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel prospects of statins as therapeutic agents in cancer.
    Pisanti S; Picardi P; Ciaglia E; D'Alessandro A; Bifulco M
    Pharmacol Res; 2014 Oct; 88():84-98. PubMed ID: 25009097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the laboratory: clinical implications for statin pleiotropy.
    Halcox JP; Deanfield JE
    Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?
    Guymer RH; Chiu AW; Lim L; Baird PN
    Surv Ophthalmol; 2005; 50(2):194-206. PubMed ID: 15749309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current questions regarding the use of statins in patients with coronary heart disease.
    Rallidis LS; Lekakis J; Kremastinos DT
    Int J Cardiol; 2007 Nov; 122(3):188-94. PubMed ID: 17399827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins: potential new indications in inflammatory conditions.
    Endres M
    Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects and cholesterol-lowering therapy.
    Shaw SM; Fildes JE; Yonan N; Williams SG
    Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic vascular protective effects of statins in perioperative medicine.
    Fang SY; Roan JN; Luo CY; Tsai YC; Lam CF
    Acta Anaesthesiol Taiwan; 2013 Sep; 51(3):120-6. PubMed ID: 24148741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.
    Mihos CG; Salas MJ; Santana O
    Cardiol Rev; 2010; 18(6):298-304. PubMed ID: 20926939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.